Email Updates

Search form

You are here

HVTN 122

Status
Ongoing
Phase
I
Objective

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of an HIV vaccine (gp145 C.6980) with aluminum hydroxide adjuvant in healthy, HIV-1-uninfected adults in the United States.

Prevention Option(s)
HIV Vaccine
Study Design
Randomized
Arms and Assigned Interventions
Description
Participants will receive 300 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.
Mode of Delivery
Intramuscular
Products
gp145 C.6980
ARMs
Experimental
Clade
C
Description
Participants will receive 100 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.
Mode of Delivery
Intramuscular
Products
gp145 C.6980
ARMs
Experimental
Clade
C
Description
Participants will receive placebo at Day 0 and Months 2 and 6.
Mode of Delivery
Intramuscular
ARMs
Placebo Comparator
Trial Sponsors
DAIDS
January 2018
May 2019
Enrollment
45
18
Years
50
Years
Population
Women
Men
Sites

New York- Physicians and Surgeons

New York
United States of America

New York Blood Center

New York, New York
United States of America

Site(s) - Philadelphia

Philadelphia, Pennsylvania
United States of America